Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

Please be advised, today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead. Thank you, Kevin. Good morning, everyone, ...

The company is now expecting 2025 revenue to range from $1.5 billion to $2.5 billion, with a midpoint of $2.0 billion, while FactSet is expecting $2.4 billion. Most of that will come in the second ...

Bridgewater Associates made a fresh bet on EV maker Tesla Inc. late last year, as it exited memory chip maker Micron ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen Richter ...

Investors seeking to outperform the market should focus their stock-picking efforts on volatile names in the consumer discretionary, information technology and communications services industries, ...

Ray Dalio’s Bridgewater Associates, which is one of the world’s largest hedge funds, made significant adjustments to its ...

The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...

These three premier ASX healthcare stocks just reported half-yearly earnings – and each saw its share price dip…So, is now the time to buy?

Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...